Sensydia
Cardio-respiratory monitoring device. It develops a wireless, non-invasive Cardio-Respiratory monitoring device that will help patients measure real-time heart function. The company is operating in stealth mode. Founded in 2015, headquartered in Los Angeles, United States. The company has raised $17.8M in funding at the series a stage. The team comprises 14 (Jun 30, 2026) employees. Backed by investors including…
Funding snapshot
About
Cardio-respiratory monitoring device. It develops a wireless, non-invasive Cardio-Respiratory monitoring device that will help patients measure real-time heart function. The company is operating in stealth mode. Founded in 2015, headquartered in Los Angeles, United States. The company has raised $17.8M in funding at the series a stage. The team comprises 14 (Jun 30, 2026) employees. Backed by investors including Orlando Health, Colle Capital, Frontier Venture Capital, NIH. The company operates in the Cardiac and Vascular Disorders sector with additional focus on Wearable Technology and Wearable Technology. Its business model centers on Cardiac. Founded in 2015, headquartered in Los Angeles, United States. The company has raised $17.8M at the Series A stage. Backed by investors including Orlando Health, Colle Capital, Frontier Venture Capital, NIH, HHS and others.
Business model
Wearable Technology > Health and Wellness Devices > Cardiac,
Disease Self Management > Cardiac and Vascular Disorders > Monitoring > Heart Health > Device > Wearable,
Healthcare IT > Value Based Care > Remote Monitoring > Hardware > Cardiology > Wearable,
Cardiac and Vascular Disorders > Medical Devices > Monitoring Devices > Hemodynamic Parameters > Home Based,
MassChallenge Batches > HealthTech > 2023
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.